Olverembatinib in chronic myeloid leukemia
DRUGS OF TODAY, vol.58, no.11, pp.531-538, 2022 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 58 Issue: 11
- Publication Date: 2022
- Doi Number: 10.1358/dot.2022.58.11.3441854
- Journal Name: DRUGS OF TODAY
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, CINAHL, EMBASE, DIALNET
- Page Numbers: pp.531-538
- Istanbul University Affiliated: No
Abstract
The introduction of tyrosine kinase inhibitors (TKIs) rep resents a new era in the management of chronic myeloid leukemia (CML). Despite their long clinical suc-cess, point mutations emerging before or during TKI treatment remain an obstacle for several cases. T315I is one of these point mutations in the tyrosine kinase domain of BCR::ABL1. It is a major cause of resistance against first-and second-generation TKIs and there-fore lowers survival rates of a small group of patients. Olverembatinib (HQP-1351, formerly GZD-824) is a novel, orally active TKI, which acts through targeting the ATP-binding site of the BCR::ABL1 tyrosine kinase. In recent studies, olverembatinib appears to be an eff-ective and safe treatment option for CML patients har-boring T315I mutation. This article mainly focuses on the efficacy and safety data of olverembatinib along with other clinically available and potentially active drugs against T315I-mutated CML.